Showing results (11-20 of 57) with videos related to
Sort By:
Pageof 6
Leukemia & Lymphoma|May 21, 2009
Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomabDirk Nagorsen, Ralf Bargou, Dominik Ruttinger, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 23, 2005
Preferential targeting of CD4-CCR5 complexes with bifunctional inhibitors: a novel approach to block HIV-1 infectionMatthias Mack, Jochen Pfirstinger, Jürgen Haas, et al.Experimental Hematology|July 6, 2021
Relationship of T- and B-cell kinetics to clinical response in patients with relapsed/refractory non-Hodgkin lymphoma treated with blinatumomabVirginie Nägele, Gerhard Zugmaier, Maria-Elisabeth Goebeler, et al.Journal of Immunological Methods|June 2, 2007
A multimarker real-time RT-PCR for MAGE-A gene expression allows sensitive detection and quantification of the minimal systemic tumor load in patients with localized cancerIngo Mecklenburg, Dorothea Weckermann, Alfred Zippelius, et al.Cancer Immunology, Immunotherapy : CII|March 24, 2010
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigenClaudia Bluemel, Susanne Hausmann, Petra Fluhr, et al.Immunobiology|January 23, 2009
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110Cornelia Haas, Eva Krinner, Klaus Brischwein, et al.International Immunology|March 22, 2005
Highly efficient antigen targeting to M-DC8+ dendritic cells via FcgammaRIII/CD16-specific antibody conjugatesInes Mende, Patrick Hoffmann, Andreas Wolf, et al.Molecular Immunology|November 7, 2006
CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysisMichael Mølhøj, Sandrine Crommer, Klaus Brischwein, et al.Current Clinical Pharmacology|May 19, 2018
Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin LymphomaYoussef Hijazi, Matthias Klinger, Andrea Kratzer, et al.Cancer Immunology, Immunotherapy : CII|March 8, 2005
Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapySonja Offner, Armin Hekele, Ulrike Teichmann, et al.Pageof 6